AGEN

AGEN's headline numbers are a mirage. Of the $114M FY2025 'revenue,' $108.6M is non-cash royalty revenue the company records only because of liability accounting on royalties it sold to HCR in 2018 — GSK remits those royalties directly to HCR, not Agenus. Actual commercial product revenue was just $4.2M of BOT+BAL sold through French compassionate-use and named-patient pathways. Likewise, the near-breakeven -$3.08M net loss (vs. -$232M in FY2024) is not a turnaround: it's flattered by a one-time $100.9M non-cash gain on deconsolidation of MiNK plus a $26.3M fair-value mark on the residual stake. Strip those out and operating income was -$20.2M with -$77.2M of operating cash burn.

The balance sheet is the disqualifier. Cash fell 92.6% to $3.00M against a $77M annual operating burn — that is weeks of runway, not quarters. Stockholders' equity is -$271M, current liabilities ($323M) exceed current assets ($133M) by ~$190M, and $44.7M of debt (up 1,555%) is now current. The MD&A's own obligations table shows $39.3M due within a year. With a $2.18B accumulated deficit, the only paths forward are massive dilution (shares already grew 51.7% in the year), asset sales, or restructuring — all bad for the $3.49 equity holder. The 49% R&D cut and 24% G&A cut signal defensive cash preservation, not disciplined growth, and gut the pipeline that would justify any biotech premium.